Introduction
The worldwide antibody drug conjugate market size is estimated to reach around USD 10.1 billion by 2026, this market is foreseen to develop with 26.3% CAGR during the forecast time period.
Market Dynamics
Significant progressions in linker technology combined with broad R&D exercises is probably going to drive the market. Antibody drug conjugates are a creative class of medication made out of antibody linked, through a chemical linker, to a cytotoxic medication. ADC is intended to profit by the high explicitness of monoclonal antibodies to convey strong cytotoxic compound specifically to antigen-communicating tumor cells.
Conventional chemotherapy is planned to destroy quickly developing tumor cells. Be that as it may, it can likewise healthy proliferating cells, which produces unfortunate reactions. Interestingly, ADC is intended to upsurge the viability of treatment and decline the foundational poisonous quality.
Expanding rate of cancer growth combined with developing geriatric populace are probably going to drive the market for Antibody-Drug Conjugates (ADC). Besides, major mechanical progressions are likewise adding to drive the development. As indicated by the World Health Organization (WHO), the quantity of individuals matured 65 years or more, is anticipated to achieve 16% of the all-out populace by 2050 from 7% in 2000. Maturing has turned into a generous hazard factor for various sicknesses including disease and others. Subsequently, the developing geriatric populace is relied upon to drive development of the market over the coming years.
Market Insights
Based on technology, the market is bifurcated into cleavable and non-cleavable linkers. These two are the most transcendent advancements used to connect cytotoxic anticancer specialists' payloads. For example, two of the top of the line ADCs-Adcetris and Kadcyla, contains cleavable and non-cleavable linkers.
It has been evaluated that cleavable linkers will observer the quickest development over the coming years attributable to the variables, for example, wide utilization of these linkers and greatest number of products in the pipeline. Moreover, in 2017 two new Pfizer's products Besponsa and Mylotarg, were affirmed for use in created areas and both contain cleavable linkers.
Market Segmentation
Market By Application
- Blood Cancer
- Breast Cancer
- Ovarian Cancer
- Lung Cancer
- Brain Tumor
Market By End-user
- Hospitals
- Clinics
- ASC
- Homecare
- Others
Market By Technology
- Cleavable Linker
- Non-cleavable Linker
Market By Geography
- North America
- Europe
- UK
- Germany
- France
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- Rest of Asia-Pacific
- Latin America
- Brazil
- Chile
- Rest of Latin America
- Middle East and Africa (MEA)
- South Africa
- Saudi Arabia
- Rest of MEA
Regional Insights
In 2017, North America was the biggest revenue producing region, trailed by Europe. The main consideration ascribing for their proceeded with strength incorporates the nearness of critical market players, for example, Seattle Genetics, Roche, Pfizer, and AbbVie. North America is the most settled market as far as the use of ADCs combined with entrenched medicinal services foundation, and patient mindfulness.
North America is anticipated to observe the quickest development over the estimate time frame as a large portion of the ADCs at present in pipeline are being produced in U.S. Additionally, the U.S. Nourishment and Drug Administration (FDA) is one of the principal administrative bodies to endorse ADC in U.S. Subsequently, these components are probably going to help showcase development in the area over the estimate time frame.
Market Participants
Few of the main player present in the global Antibody drug conjugate market are AbbVie Inc.; Seattle Genetics, Inc. .; F. Hoffmann-La Roche Ltd.; Takeda Pharmaceutical Company Limited and Pfizer Inc.
CHAPTER 1. INDUSTRY OVERVIEW
1.1. Definition and Scope
1.1.1. Definition of Antibody Drug Conjugate
1.1.2. Market Segmentation
1.1.3. List of Abbreviations
1.2. Summary
1.2.1. Market Snapshot
1.2.2. Antibody Drug Conjugate Market By Application
1.2.2.1. Global Antibody Drug Conjugate Market Revenue and Growth Rate Comparison By Application (2015-2026)
1.2.2.2. Global Antibody Drug Conjugate Market Revenue Share By Application in 2017
1.2.2.3. Blood Cancer
1.2.2.4. Breast Cancer
1.2.2.5. Ovarian Cancer
1.2.2.6. Lung Cancer
1.2.2.7. Brain Tumor
1.2.2.8. Others
1.2.3. Antibody Drug Conjugate Market By End-user
1.2.3.1. Global Antibody Drug Conjugate Market Revenue and Growth Rate Comparison By End-user (2015-2026)
1.2.3.2. Hospitals
1.2.3.3. Clinics
1.2.3.4. ASC
1.2.3.5. Homecare
1.2.3.6. Others
1.2.4. Antibody Drug Conjugate Market By Technology
1.2.4.1. Global Antibody Drug Conjugate Market Revenue and Growth Rate Comparison By Technology (2015-2026)
1.2.4.2. Cleavable Linker
1.2.4.3. Non-cleavable Linker
1.2.4.4. Others
1.2.5. Antibody Drug Conjugate Market by Geography
1.2.5.1. Global Antibody Drug Conjugate Market Revenue and Growth Rate Comparison by Geography (2015-2026)
1.2.5.2. North America Antibody Drug Conjugate Market Revenue and Growth Rate (2015-2026)
1.2.5.3. Europe Antibody Drug Conjugate Market Revenue and Growth Rate (2015-2026)
1.2.5.4. Asia-Pacific Antibody Drug Conjugate Market Revenue and Growth Rate (2015-2026)
1.2.5.5. Latin America Antibody Drug Conjugate Market Revenue and Growth Rate (2015-2026)
1.2.5.6. Middle East and Africa (MEA) Antibody Drug Conjugate Market Revenue and Growth Rate (2015-2026)
CHAPTER 2. MARKET DYNAMICS AND COMPETITION ANALYSIS
2.1. Market Drivers
2.2. Restraints and Challenges
2.3. Growth Opportunities
2.4. Porter’s Five Forces Analysis
2.4.1. Bargaining Power of Suppliers
2.4.2. Bargaining Power of Buyers
2.4.3. Threat of Substitute
2.4.4. Threat of New Entrants
2.4.5. Degree of Competition
2.5. Value Chain Analysis
2.6. Cost Structure Analysis
2.6.1. Raw Material and Suppliers
2.6.2. Manufacturing Process Analysis
2.7. Regulatory Compliance
2.8. Competitive Landscape, 2017
2.8.1. Player Positioning Analysis
2.8.2. Key Strategies Adopted By Leading Players
CHAPTER 3. MANUFACTURING PLANTS ANALYSIS
3.1. Capacity and Commercial Production Date of Global Antibody Drug Conjugate Major Manufacturers in 2017
3.2. Manufacturing Plants Distribution of Global Antibody Drug Conjugate Major Manufacturers in 2017
3.3. R&D Status and Technology Source of Global Antibody Drug Conjugate Major Manufacturers in 2017
3.4. Raw Materials Sources Analysis of Global Antibody Drug Conjugate Major Manufacturers in 2017
CHAPTER 4. ANTIBODY DRUG CONJUGATE MARKET BY APPLICATION
4.1. Global Antibody Drug Conjugate Revenue By Application
4.2. Blood Cancer
4.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.3. Breast Cancer
4.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.4. Ovarian Cancer
4.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.5. Lung Cancer
4.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.6. Brain Tumor
4.6.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.6.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.7. Other
4.7.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.7.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
CHAPTER 5. ANTIBODY DRUG CONJUGATE MARKET BY END-USER
5.1. Global Antibody Drug Conjugate Revenue By End-user
5.2. Hospitals
5.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.3. Clinics
5.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.4. ASC
5.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.5. Homecare
5.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.6. Others
5.6.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.6.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
CHAPTER 6. ANTIBODY DRUG CONJUGATE MARKET BY TECHNOLOGY
6.1. Global Antibody Drug Conjugate Revenue By Technology
6.2. Cleavable Linker
6.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.3. Non-cleavable Linker
6.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.4. Others
6.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
CHAPTER 7. NORTH AMERICA ANTIBODY DRUG CONJUGATE MARKET BY COUNTRY
7.1. North America Antibody Drug Conjugate Market Revenue and Growth Rate, 2015 - 2026 ($Million)
7.2. North America Antibody Drug Conjugate Market Revenue Share Comparison, 2015 & 2026 (%)
7.3. U.S.
7.3.1. U.S. Antibody Drug Conjugate Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
7.3.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
7.3.3. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
7.4. Canada
7.4.1. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
7.4.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
7.4.3. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
7.5. Mexico
7.5.1. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
7.5.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
7.5.3. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
CHAPTER 8. EUROPE ANTIBODY DRUG CONJUGATE MARKET BY COUNTRY
8.1. Europe Antibody Drug Conjugate Market Revenue and Growth Rate, 2015 - 2026 ($Million)
8.2. Europe Antibody Drug Conjugate Market Revenue Share Comparison, 2015 & 2026 (%)
8.3. UK
8.3.1. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
8.3.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
8.3.3. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
8.4. Germany
8.4.1. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
8.4.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
8.4.3. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
8.5. France
8.5.1. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
8.5.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
8.5.3. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
8.6. Spain
8.6.1. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
8.6.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
8.6.3. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
8.7. Rest of Europe
8.7.1. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
8.7.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
8.7.3. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
CHAPTER 9. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET BY COUNTRY
9.1. Asia-Pacific Antibody Drug Conjugate Market Revenue and Growth Rate, 2015 - 2026 ($Million)
9.2. Asia-Pacific Antibody Drug Conjugate Market Revenue Share Comparison, 2015 & 2026 (%)
9.3. China
9.3.1. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
9.3.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
9.3.3. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
9.4. Japan
9.4.1. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
9.4.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
9.4.3. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
9.5. India
9.5.1. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
9.5.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
9.5.3. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
9.6. Australia
9.6.1. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
9.6.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
9.6.3. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
9.7. South Korea
9.7.1. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
9.7.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
9.7.3. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
9.8. Rest of Asia-Pacific
9.8.1. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
9.8.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
9.8.3. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
CHAPTER 10. LATIN AMERICA ANTIBODY DRUG CONJUGATE MARKET BY COUNTRY
10.1. Latin America Antibody Drug Conjugate Market Revenue and Growth Rate, 2015 - 2026 ($Million)
10.2. Latin America Antibody Drug Conjugate Market Revenue Share Comparison, 2015 & 2026 (%)
10.3. Brazil
10.3.1. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
10.3.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
10.3.3. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
10.4. Argentina
10.4.1. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
10.4.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
10.4.3. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
10.5. Rest of Latin America
10.5.1. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
10.5.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
10.5.3. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
CHAPTER 11. MIDDLE EAST ANTIBODY DRUG CONJUGATE MARKET BY COUNTRY
11.1. Middle East Antibody Drug Conjugate Market Revenue and Growth Rate, 2015 - 2026 ($Million)
11.2. Middle East Antibody Drug Conjugate Market Revenue Share Comparison, 2015 & 2026 (%)
11.3. Saudi Arabia
11.3.1. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
11.3.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
11.3.3. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
11.4. UAE
11.4.1. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
11.4.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
11.4.3. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
11.5. Rest of Middle East
11.5.1. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
11.5.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
11.5.3. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
CHAPTER 12. AFRICA ANTIBODY DRUG CONJUGATE MARKET BY COUNTRY
12.1. Africa Antibody Drug Conjugate Market Revenue and Growth Rate, 2015 - 2026 ($Million)
12.2. Africa Antibody Drug Conjugate Market Revenue Share Comparison, 2015 & 2026 (%)
12.3. South Africa
12.3.1. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
12.3.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
12.3.3. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
12.4. Egypt
12.4.1. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
12.4.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
12.4.3. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
12.5. Rest of Africa
12.5.1. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
12.5.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
12.5.3. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
CHAPTER 13. COMPANY PROFILE
13.1. AbbVie Inc.
13.1.1. Company Snapshot
13.1.2. Overview
13.1.3. Financial Overview
13.1.4. Type Portfolio
13.1.5. Key Developments
13.1.6. Strategies
13.2. Seattle Genetics, Inc.
13.2.1. Company Snapshot
13.2.2. Overview
13.2.3. Financial Overview
13.2.4. Type Portfolio
13.2.5. Key Developments
13.2.6. Strategies
13.3. F. Hoffmann-La Roche Ltd.
13.3.1. Company Snapshot
13.3.2. Overview
13.3.3. Financial Overview
13.3.4. Type Portfolio
13.3.5. Key Developments
13.3.6. Strategies
13.4. Takeda Pharmaceutical Company Limited
13.4.1. Company Snapshot
13.4.2. Overview
13.4.3. Financial Overview
13.4.4. Type Portfolio
13.4.5. Key Developments
13.4.6. Strategies
13.5. Pfizer Inc.
13.5.1. Company Snapshot
13.5.2. Overview
13.5.3. Financial Overview
13.5.4. Type Portfolio
13.5.5. Key Developments
13.5.6. Strategies
13.6. Others
13.6.1. Company Snapshot
13.6.2. Overview
13.6.3. Financial Overview
13.6.4. Type Portfolio
13.6.5. Key Developments
13.6.6. Strategies
CHAPTER 14. RESEARCH APPROACH
14.1. Research Methodology
14.1.1. Initial Data Search
14.1.2. Secondary Research
14.1.3. Primary Research
14.2. Assumptions and Scope
![Antibody Drug Conjugate Market (By Application: Blood Cancer [Leukemia, Lymphoma], Breast Cancer, Ovarian Cancer, Lung Cancer, Brain Tumor; By End-user: Hospitals, Clinics, ASC, Homecare, Others; By Technology: Cleavable Linker, Non-cleavable Linker) - Global Industry Analysis, Market Size, Opportunities and Forecast, 2018 - 2026](assets/images/format-png.png "Antibody Drug Conjugate Market (By Application: Blood Cancer [Leukemia, Lymphoma], Breast Cancer, Ovarian Cancer, Lung Cancer, Brain Tumor; By End-user: Hospitals, Clinics, ASC, Homecare, Others; By Technology: Cleavable Linker, Non-cleavable Linker) - Global Industry Analysis, Market Size, Opportunities and Forecast, 2018 - 2026")
